Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Hypothyroidism | Research

Analysis of correlative risk factors for radiation-induced hypothyroidism in head and neck tumors

Authors: Chan Wang, Yanjie Hou, Lili Wang, Ye Yang, Xianfeng Li

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Objective

The aim of the study is to identify clinical and dosimetric factors that could predict the risk of radiation-induced hypothyroidism(RIHT) in head and neck cancer(HNC) patients following intensity-modulated radiotherapy(IMRT).

Methods

A total of 103 HNC patients were included in our study. General clinical characteristic and dosimetric data of all recruited patients were analyzed, respectively. The univariate and multivariate logistic regression anlalysis were successively conducted to identify optimal predictors, which aim to construct the nomogram. And the joint prediction was performed.

Results

The incidence of patients with HNC was 36.9% (38/103). Among the clinical factors, gender, N stage, chemotherapy, frequency of chemotherapy and surgery involving the thyroid were related to RIHT. Logistic regression analysis showed that thyroid volume, Dmean, VS45, VS50, VS60 and V30,60 were independent predictors of RIHT, which were also incorporated in the nomogram. An AUC of 0.937 (95%CI, 0.888–0.958) also was showed outstanding resolving ability of the nomogram. When the volume of the thyroid was greater than 10.6 cm3, the incidence of RIHT was 14.8%, and when the volume of the thyroid was equal to or smaller than 10.6 cm3, the incidence was 72.5%. The incidence rates of RIHT in the group with VS60≦8.4cm3 and VS60 > 8.4cm3 were 61.4% and 19.3%, respectively.

Conclusions

Thyroid volume and thyroid VS60 are independent predictors of RIHT in patients with HNC. Moreover, more attention should be paid to patients with thyroid volume ≤ 10.6cm3. Thyroid VS60 > 8.4cm3 may be a useful threshold for predicting the development of RIHT. The nomogram conducted by the research may become a potential and valuable tool that could individually predict the risk of RIHT for HNC patients.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
2.
go back to reference Beddok A, Vela A, Calugaru V, et al. Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges. Radiother Oncol. 2020;147:30–9.CrossRefPubMed Beddok A, Vela A, Calugaru V, et al. Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges. Radiother Oncol. 2020;147:30–9.CrossRefPubMed
3.
go back to reference Bakhshandeh M, Hashemi B, Mahdavi SR, et al. Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(2):514–21.CrossRefPubMed Bakhshandeh M, Hashemi B, Mahdavi SR, et al. Normal tissue complication probability modeling of radiation-induced hypothyroidism after head-and-neck radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(2):514–21.CrossRefPubMed
4.
go back to reference Liu CH, Chang JT, Lee TH, et al. Hypothyroidism and risks of cerebrovascular complications among patients with head and neck cancer after radiotherapy. BMC Neurol. 2021;21(1):30.CrossRefPubMedPubMedCentral Liu CH, Chang JT, Lee TH, et al. Hypothyroidism and risks of cerebrovascular complications among patients with head and neck cancer after radiotherapy. BMC Neurol. 2021;21(1):30.CrossRefPubMedPubMedCentral
5.
go back to reference Floriani C, Gencer B, Collet TH, et al. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Eur Heart J. 2018;39(7):503–7.CrossRefPubMed Floriani C, Gencer B, Collet TH, et al. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Eur Heart J. 2018;39(7):503–7.CrossRefPubMed
6.
7.
go back to reference Rodondi N, den Elzen WP, Bauer DC, et al. Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.CrossRefPubMedPubMedCentral Rodondi N, den Elzen WP, Bauer DC, et al. Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.CrossRefPubMedPubMedCentral
8.
go back to reference Aggarwal K, Thakur S, Rao V, et al. Radiation induced hypothyroidism - Why is early intervention necessary? Oral Oncol. 2020;103:104444.CrossRefPubMed Aggarwal K, Thakur S, Rao V, et al. Radiation induced hypothyroidism - Why is early intervention necessary? Oral Oncol. 2020;103:104444.CrossRefPubMed
9.
go back to reference Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.CrossRefPubMedPubMedCentral Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.CrossRefPubMedPubMedCentral
10.
go back to reference Sommat K, Ong WS, Hussain A, et al. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2017;98(3):574–80.CrossRefPubMed Sommat K, Ong WS, Hussain A, et al. Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2017;98(3):574–80.CrossRefPubMed
11.
go back to reference Nishiyama K, Kozuka T, Higashihara T, et al. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys. 1996;36(5):1221–4.CrossRefPubMed Nishiyama K, Kozuka T, Higashihara T, et al. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys. 1996;36(5):1221–4.CrossRefPubMed
12.
go back to reference Fan CY, Lin CS, Chao HL, et al. Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: a population-based cohort study. Radiother Oncol. 2017;123(3):394–400.CrossRefPubMed Fan CY, Lin CS, Chao HL, et al. Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: a population-based cohort study. Radiother Oncol. 2017;123(3):394–400.CrossRefPubMed
13.
go back to reference Jain PV, Das A, Manikantan K, et al. Radiation-induced hypothyroidism in patients of oral squamous cell carcinoma: A retrospective analysis of 195 patients. Indian J Cancer. 2022;59(4):480–4.PubMed Jain PV, Das A, Manikantan K, et al. Radiation-induced hypothyroidism in patients of oral squamous cell carcinoma: A retrospective analysis of 195 patients. Indian J Cancer. 2022;59(4):480–4.PubMed
14.
go back to reference Lee V, Chan SY, Choi CW, et al. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. Clin Oncol (R Coll Radiol). 2016;28(8):e52-60.CrossRefPubMed Lee V, Chan SY, Choi CW, et al. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. Clin Oncol (R Coll Radiol). 2016;28(8):e52-60.CrossRefPubMed
15.
go back to reference Akgun Z, Atasoy BM, Ozen Z, et al. V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck. Radiat Oncol. 2014;9:104.CrossRefPubMedPubMedCentral Akgun Z, Atasoy BM, Ozen Z, et al. V30 as a predictor for radiation-induced hypothyroidism: a dosimetric analysis in patients who received radiotherapy to the neck. Radiat Oncol. 2014;9:104.CrossRefPubMedPubMedCentral
16.
go back to reference Jia-Mahasap B, Assavanopakun K, Chitapanarux I, et al. Incidence of radiation-induced hypothyroidism following head and neck irradiation: a single-center analysis. Rep Pract Oncol Radiother. 2022;27(3):479–89.PubMedPubMedCentral Jia-Mahasap B, Assavanopakun K, Chitapanarux I, et al. Incidence of radiation-induced hypothyroidism following head and neck irradiation: a single-center analysis. Rep Pract Oncol Radiother. 2022;27(3):479–89.PubMedPubMedCentral
17.
go back to reference Diaz R, Jaboin JJ, Morales-Paliza M, et al. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):468–76.CrossRefPubMed Diaz R, Jaboin JJ, Morales-Paliza M, et al. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;77(2):468–76.CrossRefPubMed
18.
go back to reference Colevas AD, Read R, Thornhill J, et al. Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2001;51(3):599–604.CrossRefPubMed Colevas AD, Read R, Thornhill J, et al. Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2001;51(3):599–604.CrossRefPubMed
19.
go back to reference Luo R, Wu VWC, He B, et al. Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. BMC Cancer. 2018;18(1):575.CrossRefPubMedPubMedCentral Luo R, Wu VWC, He B, et al. Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. BMC Cancer. 2018;18(1):575.CrossRefPubMedPubMedCentral
20.
go back to reference Vogelius IR, Bentzen SM, Maraldo MV, et al. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. Cancer. 2011;117(23):5250–60.CrossRefPubMed Vogelius IR, Bentzen SM, Maraldo MV, et al. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. Cancer. 2011;117(23):5250–60.CrossRefPubMed
21.
go back to reference Alba JR, Basterra J, Ferrer JC, et al. Hypothyroidism in patients treated with radiotherapy for head and neck carcinoma: standardised long-term follow-up study. J Laryngol Otol. 2016;130(5):478–81.CrossRefPubMed Alba JR, Basterra J, Ferrer JC, et al. Hypothyroidism in patients treated with radiotherapy for head and neck carcinoma: standardised long-term follow-up study. J Laryngol Otol. 2016;130(5):478–81.CrossRefPubMed
22.
go back to reference Zhou L, Chen J, Shen W. Thyroid V50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study. Radiat Oncol. 2020;15(1):68.CrossRefPubMedPubMedCentral Zhou L, Chen J, Shen W. Thyroid V50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study. Radiat Oncol. 2020;15(1):68.CrossRefPubMedPubMedCentral
23.
go back to reference Zhou L, Chen J, Tao CJ, et al. Association between Cervical Lymph Node Metastasis and the Incidence of Radiation-Induced Hypothyroidism in Nasopharyngeal Carcinoma. J Oncol. 2022;2022:5693575.CrossRefPubMedPubMedCentral Zhou L, Chen J, Tao CJ, et al. Association between Cervical Lymph Node Metastasis and the Incidence of Radiation-Induced Hypothyroidism in Nasopharyngeal Carcinoma. J Oncol. 2022;2022:5693575.CrossRefPubMedPubMedCentral
24.
go back to reference Chyan A, Chen J, Shugard E, et al. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014;9:269.CrossRefPubMedPubMedCentral Chyan A, Chen J, Shugard E, et al. Dosimetric predictors of hypothyroidism in oropharyngeal cancer patients treated with intensity-modulated radiation therapy. Radiat Oncol. 2014;9:269.CrossRefPubMedPubMedCentral
25.
go back to reference Zhai RP, Kong FF, Du CR. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study. Oral Oncol. 2017;68:44–9.CrossRefPubMed Zhai RP, Kong FF, Du CR. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study. Oral Oncol. 2017;68:44–9.CrossRefPubMed
26.
go back to reference Lee AW, Ng WT, Pan JJ, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(3):567–80.CrossRefPubMed Lee AW, Ng WT, Pan JJ, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2019;105(3):567–80.CrossRefPubMed
27.
go back to reference Lertbutsayanukul C, Kitpanit S, Prayongrat A, et al. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. J Radiat Res. 2018;59(4):446–55.CrossRefPubMedPubMedCentral Lertbutsayanukul C, Kitpanit S, Prayongrat A, et al. Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. J Radiat Res. 2018;59(4):446–55.CrossRefPubMedPubMedCentral
28.
go back to reference Chow JCH, Cheung KM, Cheung GTC, et al. Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. Clin Transl Radiat Oncol. 2022;33:83–92.PubMedPubMedCentral Chow JCH, Cheung KM, Cheung GTC, et al. Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. Clin Transl Radiat Oncol. 2022;33:83–92.PubMedPubMedCentral
29.
go back to reference Peng L, Mao YP, Huang CL, et al. A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. Front Oncol. 2020;10:551255.CrossRefPubMedPubMedCentral Peng L, Mao YP, Huang CL, et al. A New Model for Predicting Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. Front Oncol. 2020;10:551255.CrossRefPubMedPubMedCentral
30.
go back to reference Prpic M, Kruljac I, Kust D, et al. Dose-volume derived nomogram as a reliable predictor of radiotherapy-induced hypothyroidism in head and neck cancer patients. Radiol Oncol. 2019;53(4):488–96.CrossRefPubMedPubMedCentral Prpic M, Kruljac I, Kust D, et al. Dose-volume derived nomogram as a reliable predictor of radiotherapy-induced hypothyroidism in head and neck cancer patients. Radiol Oncol. 2019;53(4):488–96.CrossRefPubMedPubMedCentral
31.
go back to reference Zhu MY, Wu HJ, Miao JJ, et al. Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose. Oral Oncol. 2021;120:105378.CrossRefPubMed Zhu MY, Wu HJ, Miao JJ, et al. Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose. Oral Oncol. 2021;120:105378.CrossRefPubMed
Metadata
Title
Analysis of correlative risk factors for radiation-induced hypothyroidism in head and neck tumors
Authors
Chan Wang
Yanjie Hou
Lili Wang
Ye Yang
Xianfeng Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11749-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine